Weight loss at maximum dose
From separate clinical trials — no direct head-to-head comparison exists for obesity.
For a 240 lb person. Oral Wegovy figure is with full adherence to dosing instructions. Individual results vary substantially.
The real difference: daily routine
This routine is strict — skipping it reduces the drug's effectiveness.
The only oral GLP-1 with this flexibility. Good for variable schedules or shift work.
Important: No head-to-head obesity trial exists between these two drugs. The weight loss figures come from separate clinical trials with different designs. An indirect comparison funded by Novo Nordisk (Oral Wegovy's maker) found oral semaglutide showed about 3 percentage points more weight loss with lower discontinuation rates. A separate trial in type 2 diabetes (using a lower semaglutide dose) found orforglipron performed better. Different populations, different doses, different results.
Monthly cost
Self-pay / manufacturer programs. Insurance coverage varies.
At the starting dose, both cost ~$149. At maximum dose, Foundayo costs more than double. Foundayo offers $25/mo with eligible commercial insurance; Medicare Part D coverage expected from July 2026 (~$50/mo).
Consider Oral Wegovy if you...
Consider Foundayo if you...
Tirzepatide injection (Zepbound): ~20.9% average weight loss. Semaglutide injection (Wegovy): ~14.9% with proven heart benefits. Both are weekly injections.
See the injection comparison →Not sure where to start? Our 2-minute quiz can help.
Take the quiz →Built with agentic AI tools and not a substitute for medical advice
Last reviewed: June 2026